These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
183 related items for PubMed ID: 34353071
1. Clinical efficacy and safety of mecapegfilgrastim in small cell lung cancer as primary prophylaxis of neutropenia post chemotherapy: a retrospective analysis. Gu X, Zhang Y. Ann Palliat Med; 2021 Jul; 10(7):7841-7846. PubMed ID: 34353071 [Abstract] [Full Text] [Related]
2. A Randomized Multicenter Phase III Study of Single Administration of Mecapegfilgrastim (HHPG-19K), a Pegfilgrastim Biosimilar, for Prophylaxis of Chemotherapy-Induced Neutropenia in Patients With Advanced Non-Small-Cell Lung Cancer (NSCLC). Zhou C, Huang Y, Wang D, An C, Zhou F, Li Y, Chen G, Wu C, He J, Wu G, Song X, Gao J, Liu W, Li B, Shi J, Huang C, Yu J, Feng J, Yue H, Shi M, Xia J. Clin Lung Cancer; 2016 Mar; 17(2):119-27. PubMed ID: 26781346 [Abstract] [Full Text] [Related]
3. Prophylactic administration of mecapegfilgrastim after chemotherapy in patients with lymphoma. Zheng M, Wen X, Su L. Ann Palliat Med; 2021 Dec; 10(12):12055-12060. PubMed ID: 35016412 [Abstract] [Full Text] [Related]
4. Cost-effectiveness analysis of mecapegfilgrastim and recombinant human granulocyte stimulating factor for primary prophylaxis of chemotherapy-induced neutropenia in non-small cell lung cancer. Gu YL, Sun ZX, Sun Y, Guan X, Jiang DL. Int J Clin Pharmacol Ther; 2024 Mar; 62(3):115-121. PubMed ID: 38263810 [Abstract] [Full Text] [Related]
6. [Treatment of chemotherapy-induced neutropenia pegylated recombinant human granulocyte colony-stimulating factor: a multi-center randomized controlled phase II clinical study]. Shi YK, He XH, Yang S, Wang HQ, Jiang ZF, Zhu YZ, Ke XY, Zhang Y, Liu YP, Zhang WJ, Wang Z, Shi QZ, Xie XD, Zhang HL, Wang JJ, Luo DY, Zheng QS, Sun RY. Zhonghua Yi Xue Za Zhi; 2006 Dec 26; 86(48):3414-9. PubMed ID: 17313855 [Abstract] [Full Text] [Related]
9. Efficacy and safety of 3 mg pegylated recombinant human granulocyte colony-stimulating factor as support to chemotherapy for lung cancer. Ji X, Xu L, Pan P, Xu Z, Wang A, Li Y. Thorac Cancer; 2022 Jan 26; 13(1):117-125. PubMed ID: 34791805 [Abstract] [Full Text] [Related]
10. [Phase I clinical trail of intravenous pegylated recombinant human granulocyte colony-stimulating factor]. Shi YK, Liu P, Yang S, Han XH, He XH, Ai B, Qin Y, Li B, Huang DZ, Zhang CG, Sun Y. Ai Zheng; 2006 Apr 26; 25(4):495-500. PubMed ID: 16613688 [Abstract] [Full Text] [Related]
11. PEG-rhG-CSF for prophylaxis of neutropenia after chemotherapy in patients with non-small cell lung cancer: A multicenter, prospective, randomized study. Sun XS, Wang Z, Ren SH, Zhang HL, Liu LJ, Du HB, Liu XW, Liu JF. Thorac Cancer; 2022 Sep 26; 13(17):2429-2435. PubMed ID: 35859328 [Abstract] [Full Text] [Related]
14. Efficacy and safety of mecapegfilgrastim for prophylaxis of chemotherapy-induced neutropenia in patients with breast cancer: a randomized, multicenter, active-controlled phase III trial. Xu F, Zhang Y, Miao Z, Zeng X, Wu B, Cai L, Liu J, Wang S, Hu X, Zheng W, Chen Z, Yang Q, Jiang Z. Ann Transl Med; 2019 Sep 26; 7(18):482. PubMed ID: 31700918 [Abstract] [Full Text] [Related]
20. [The role of prophylactic use of pegylated recombinant human granulocyte colony-stimulating factor(PEG-rhG-CSF) in breast cancer receiving adjuvant chemotherapy]. Zhang JY, Liu YX, Wang H, Mi L, Song GH, Jiang HF, Yan Y, Shao B, Kong WY, Zhang RY, Ran R, Liu XR, Wang J, Lin YT, Li HP. Zhonghua Yi Xue Za Zhi; 2018 Sep 11; 98(34):2718-2721. PubMed ID: 30220167 [Abstract] [Full Text] [Related] Page: [Next] [New Search]